ClinicalTrials.gg
RecruitingNCT06741007Updated Nov 18, 2026

Correlation of Pelvic Sentinel Lymph Node With Superficial Vein

An interventional study of Retroperitoneal pelvic lymphatic and uterine vessel dissection in Sentinel Lymph Node, Superficial Uterine Vein and Deep Uterine Vein, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 18, 2026Now RecruitingFirst site in Turkey (Türkiye)+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Pelvic Sentinel Lymph Node (SLN) biopsy is an important integral part of endometrial surgery. Although SLN is usually found on internal iliac artery, location is variable. Lymphatic pathways in pelvis determines the location (Obturator, internal iliac or external iliac vessel locations). Since it is accepted that the lymphatic channel formation during embryologic life follows venous system formation investigators hypothesized that the presence or absence of superior or deep uterine vein may determine the location of sentinel lymph node

Read the detailed description

Endometrial cancer is the most common gynecologic cancer. Treatment and prognosis depends on the surgical staging of the apparently early stage disease including the evaluation of lymphatic status of the disease. Detection of positive lymph node upstages the apparently early stage endometrial cancer. However, systematic lymphadenectomy carries immediate and long term risks for patients including bleeding, massive transfusions, prolongation of operation time, serious major vessel and major abdominal organ injury and death.

Sentinel lymph node biopsy (SLNB) procedure is the biopsy of one or two lymph node(s) which represents the lymph node basin draining the area of malignancy. This biopsy may potentially eliminate the need systemic pelvic / para-aortic lymphadenectomy which harbours potential complications. Although SLNB became an standard procedure in endometrial cancer, available data on the SLNB in endometrial cancer is variable. The relevant literature suggests that the detection rate of sentinel lymph node using various tracer agents are between %70-98, even with lower for bilateral pelvic detection and para-aortic sentinel lymph node(s). The most commonly used tracer agent is fluorescent indocyanine green (ICG). Although SLN is usually found on internal iliac artery during surgery, location is variable. Lymphatic pathways in pelvis determines the location (Obturator, internal iliac or external iliac locations). Since it is accepted that the lymphatic channel formation during embryologic life follows venous system formation investigators hypothesized that the presence or absence of right or left superior (SUV) or deep uterine vein (DUV), which actually are highly variable, may determine the location of sentinel lymph node.

So investigators aims to find any correlation between the location of SLN (obturator, external iliac and internal iliac) and the presence of SUV or DUV unilaterally or bilaterally.

02

Conditions studied

  • Sentinel Lymph Node
  • Superficial Uterine Vein
  • Deep Uterine Vein

Keywords

  • sentinel lymph node
  • uterine vein
  • uterine artery
03

In context

Lead sponsor

Istanbul University is the lead sponsor of 514 studies on the registry; 78 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all women with early stage endometrial cancer who will be operated for staging

Exclusion criteria

Exclusion Criteria:

Previous radiotheraphy Previous pelvic retropelvic LN dissection Women with any disease that precludes pelvic retropelvic LN dissection (such as peritoneal dialysis)

-

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single arm study using ICG as a sentinel lymph node agent in early stage endometrium cancer

    Single arm study using ICG as a sentinel lymph node agent to detect the location of SLN in correlation with the presence or absence of superficial or deep uterine vein in early stage endometrial cancer

    Procedure: Retroperitoneal pelvic lymphatic and uterine vessel dissection

Interventions

  • ProcedureRetroperitoneal pelvic lymphatic and uterine vessel dissection

    ICG injection to cervix uteri at 3 and 9 o'clock followed by laparoscopic dissection of retroperitoneal space to detect uterine vessels (uterine arteries, SUVs and DUVs) bilaterally in addition to detect the location and biopsy of SLN stained by ICG.

06

What researchers measure

Primary outcomes

  1. Detection rate and localisation of SLN in correlation with the presence or absence of uterine veins bilaterally

    The location of SLN ( obturator, external iliac and internal iliac) will be defined in percentages for each side of pelvis in relation to presence or absence of uterine vessels.

    Time frame: Two years

07

Study locations

1 of 1 sites recruiting
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology
    Istanbul, Turkey, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Ribatti D. Historical overview of lymphangiogenesis. Curr Opin Immunol. 2018 Aug;53:161-166. doi: 10.1016/j.coi.2018.04.027. Epub 2018 May 19. PubMed 29787938 ↗
  • Kimmig R, Thangarajah F, Buderath P. Sentinel Lymph node detection in endometrial cancer - Anatomical and scientific facts. Best Pract Res Clin Obstet Gynaecol. 2024 Jun;94:102483. doi: 10.1016/j.bpobgyn.2024.102483. Epub 2024 Feb 15. PubMed 38401483 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2027; primary completion for Dec 2027, 10 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Dec 2024 → Feb 2027, primary completion Aug 2026 → Dec 2027 and completion Sep 2026 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Dec 18, 2024
StartEst.
Feb 2027was Dec 2024
Primary completionEst.
Dec 2027was Aug 2026
CompletionEst.
Jun 2028was Sep 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
Nov 18, 2026
Start date
Dec 22, 2024→Feb 2027
Nov 18, 2026
Primary completion
Aug 22, 2026→Dec 2027
Nov 18, 2026
Study completion
Sep 15, 2026→Jun 2028
Nov 18, 2026
Enrollment
100→50
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
    Start date Dec 22, 2024→Feb 2027
    Primary completion Aug 22, 2026→Dec 2027
    Study completion Sep 15, 2026→Jun 2028
    Enrollment 100→50
    + 5 other changes: identifiers, verification date, oversight details, criteria formatting and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06741007
Responsible party
Mustafa Albayrak (Principal Investigator, Istanbul University) — Principal investigator
First posted
Dec 18, 2024
Start date
Feb 2027 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Mustafa Albayrak, MD,Gynecologic Oncology Fellow
Contact
mustafaalbayrak@icloud.com
+90 532 6871051
Yagmur Minareci, M.D.,Gynec. Oncol Specialist
Contact
yagmurminareci@gmail.com
+905053574361

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion